The estimated Net Worth of Group, Llc Green Jeremy Red... is at least $30.4 Milion dollars as of 26 December 2023. Group Red owns over 44,630 units of AlloVir stock worth over $10,017,095 and over the last 9 years Group sold ALVR stock worth over $20,408,456.
Group has made over 28 trades of the AlloVir stock since 2015, according to the Form 4 filled with the SEC. Most recently Group bought 44,630 units of ALVR stock worth $166,024 on 26 December 2023.
The largest trade Group's ever made was buying 3,703,704 units of AlloVir stock on 25 September 2018 worth over $50,000,004. On average, Group trades about 218,464 units every 32 days since 2015. As of 26 December 2023 Group still owns at least 13,180,388 units of AlloVir stock.
You can see the complete history of Group Red stock trades at the bottom of the page.
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... a Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
AlloVir executives and other stock owners filed with the SEC include: